VC: Immatics gains $52.6M in second round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Immatics [1]
Germany

$52.6M
Second

Wellington Partners and 3i

Much of that will be used to fund two clinical trials for the company's cancer therapies.

CoDa Therapeutics [2]
New Zealand

$10M
First

Domain Associates and GBS Ventures

The money has been earmarked for clinical trials of its tissue repair program.

REGiMMUNE [3]
Mountain View, CA

$4.2M
Second

NIF SMBC Ventures

Proceeds from the financing will be used to further the preclinical development of REGiMMUNE's first two product candidates, RGI-2001 and RGI-1001.